Skip to main content
Publications
Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-99. doi: 10.1200/JCO.23.00170
Shamarina D, Sluga-O'Callaghan M, Kassianos G, Marijam A, Dave V, Davenport E, Andani A, Curran D, Dewda P, Steffen R. Knowledge, attitudes, and practices of European healthcare professionals towards hepatitis A and hepatitis B vaccination in at-risk adults. Vaccines (Basel). 2023 Oct 26;11(1645):1-19. doi: 10.3390/vaccines11111645
Moehler M, Wyrwicz L, Blum S, Chen C, Wang J, Davenport E, Nathani R, Kondo K, Elimova E. Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer(GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C). Presented at the ESMO World Congress on Gastrointestinal Cancer 2023; June 28, 2023. Barcelona, Spain.